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ABSTRACT: Pemetrexed (PMX) is a key drug for the
management of malignant pleural mesothelioma (MPM).
However, its therapeutic efficacy is cruelly restricted in many
clinical settings by the overexpression of thymidylate synthase
(TS) gene. Recently, we emphasized the efficacy of locally
administered shRNA designed against TS gene in enhancing
the cytotoxic effect of PMX against orthotopically implanted
MPM cells in tumor xenograft tumor model. Herein, we
explored the efficiency of systemic, rather than local, delivery
of TS RNAi molecule in sensitizing MPM cells to the cytotoxic
effect of PMX. We here designed a PEG-coated TS shRNA-
lipoplex (PEG-coated TS shRNA-lipoplex) for systemic injection. PEG modification efficiently delivered TS shRNA in the
lipoplex to tumor tissue following intravenous administration as indicated by a significant suppression of TS expression level in
tumor tissue. In addition, the combined treatment of PMX with systemic injection of PEG-coated TS shRNA-lipoplex exerted a
potent antitumor activity in a s.c. xenograft tumor model, compared to a single treatment with either PMX or PEG-coated TS
shRNA-lipoplex. Metastasis, or the spread, of mesothelioma substantially dedicates the effectiveness of treatment options. The
systemic, in addition to local, delivery of tumor targeted anti-TS RNAi system we propose in this study might be an effective
option to extend the clinical utility of PMX in treating malignant mesothelioma.
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■ INTRODUCTION
Malignant pleural mesothelioma (MPM) is a locally invasive
tumor mostly associated with past exposure to asbestos.1−3
Treatment strategies of MPM range from traditional chemo-
therapy to radical procedures to remove the cancerous tissue.
However, these therapeutic strategies showed poor prognosis
due to either the development of drug resistance or the
dissemination of the tumor to neighboring areas leading to
“cancer metastasis”.4,5
Pemetrexed (PMX), a relatively novel multitargeted
antifolate, is able to simultaneously inhibit multiple folate-
dependent enzymes involved in the synthesis of purines and
pyrimidines. PMX, as a single gent, has shown modest activity
in a phase II trial of patients with MPM,6 and more recently, it
has been approved in combination with cisplatin as first-line
treatment of MPM.7 However, the overall therapeutic outcome
of patients with MPM remains very poor with response rates of
approximately 40%. Many reports have emphasized a
correlation between high expression levels of thymidylate
synthase (TS), an essential precursor for DNA synthesis,8,9 and
reduced sensitivity to PMX in different types of tumors
including colon, lung, and advanced breast cancer.10−13
Recently, we investigated the efficacy of chemically
synthesized short hairpin RNA targeting TS (TS shRNA) in
suppressing the TS expression and thereby modulating the
cytotoxic effect of PMX against human mesotheliomal cell line,
MSTO-211H. In that study, we showed that intrapleural “local”
injection of non-PEGylated TS shRNA-lipoplexes repressed the
expression of TS mRNA in human malignant mesotheliomal
MSTO-211H cells and suppressed tumor progression. In
addition, the combined therapy of TS shRNA-lipoplex and
PMX significantly suppressed the progression of orthotopic
thoracic tumors, in tandem with prolonging the survival of mice
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inoculated orthotopically with MSTO-211H cells, compared to
a single treatment with either PMX or TS shRNA-lipoplex.14
It is worth noting that MPM cells are not confined in the
thoracic cavity but that they have the potential to disseminate
not only to neighboring tissues/organs such as regional lymph
nodes, pericardium, peritoneum, and chest wall but much
farther to reach the brain.15,16 In addition, the therapeutic
efficacy of intrapleurally administered therapeutic agents might
be compromised, on the one hand, by the widespread
distribution of thoracic tumors throughout the whole pleura
and nearby tissues/organs and, on the other, by the excessive
pleural effusion associated with MPM.17 In this study, therefore,
we focused on evaluating the effectiveness of systemic
administration of TS shRNA-lipoplex in sensitizing the
mesotheliomal cells to the cytotoxic effect of PMX, using a
subcutaneous xenograft mouse model. For systemic admin-
istration purpose, the composition of liposome of TS shRNA-
lipoplex was manipulated to obtain PEG-coated TS shRNA-
lipoplex. Inclusion of cholesterol, which has a membrane
stabilizing effect, within liposomal membrane and grafting the
hydrophilic polymer polyethylene glycol (PEG) onto the
surface of liposomes were applied in order to enhance the in
vivo stability/pharmacokinetics of administered TS shRNA-
lipoplex following their systemic administration.18−20 We here
showed that combined treatment of PMX with systemic
injection of PEG-coated TS shRNA-lipoplex significantly
suppressed tumor growth in a subcutaneous xenograft mouse
model. It appears that systemic delivery of tumor targeted anti-
TS RNAi molecule along with PMX treatment might be an
effective therapeutic option, in addition to local delivery, in
treating mesothelioma showing either localized or distant
“metastasis”.
■ MATERIALS AND METHODS
Materials. Pemetrexed disodium (PMX) was purchased
from Eli Lilly (IN, USA). 1,2-Distearoyl-sn-glycero-3-phos-
phoethanol-amine-n-[methoxy(polyethylene glycol)-2000]
(mPEG2000-DSPE), 1-palmitoyl-2-oleoylphosphatidylcholine
(POPC), and dioleoylphosphatidylethanolamine (DOPE)
were kindly provided by NOF (Tokyo, Japan). A cationic
lipid, O,O′-ditetradecanoyl-N-(alpha-trimethyl ammonio ace-
tyl) diethanolamine chloride (DC-6-14) was purchased from
Sogo Pharmaceutical (Tokyo, Japan). Cholesterol (CHOL)
was purchased from Wako Pure Chemical (Osaka, Japan).
Opti-MEM I and Lipofectamine RNAiMAX were purchased
from Invitrogen (CA, USA). 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) was obtained from
Nacalai Tesque (Kyoto, Japan). All other reagents were of
analytical grade.
Animals and Tumor Cell Line. BALB/c nu/nu mice
(male, 5-week-old) were purchased from Japan SLC (Shizuoka,
Japan). Animals were allowed access to mouse chow and water
and were handled under aseptic conditions. All animal
experiments were conducted in alignment with the guidelines
of Animal and Ethics Review Committee of Tokushima
University. Among different human malignant pleural meso-
thelioma (MPM) cell lines, MSTO-211H cell line was chosen
for this study based on the pronounced expression-level of TS
gene.21 A human MPM cell line, MSTO-211H, was purchased
from the American Type Culture Collection (VA, USA) and
was cultured in RPMI-1640 medium (Wako Pure Chemical)
supplemented with 10% fetal bovine serum FBS (Japan
Bioserum, Hiroshima, Japan) and maintained at 37 °C in a
5% CO2/air incubator.
Chemically Synthesized shRNAs. Purified chemically
synthesized shRNAs were purchased from Hokkaido System
Science (Sapporo, Japan). Two shRNAs were designed; one to
target TS (TS shRNA) and the other was nonspecific (NS
shRNA, not to target any gene in human and mouse genome).
The sequence of shRNA against TS was 5′-GUAACA-
CCAUCGAUCAUGAUAGUGCUCCUGGUUGUCA-
UGAUCGAUGGUGUUACUU-3′ and for a nonspecific
shRNA was 5′-UCUUAAUCGCGUAUAAGGCUAGU-
GCUCCUGGUUGGCCUUAUACGCGAUUAAGAUU-3′.
shRNAs were reconstituted in RNase free TE buffer at a final
concentration of 100 μmol/L.
Preparation of shRNA-Lipoplex for in Vitro Trans-
fection.MSTO-211H cells were transfected with shRNA using
Lipofectamine RNAiMAX (LfRNAiMAX, Invitogen, CA, USA)
according to the manufacturer’s instructions. In brief, 300 pmol
of shRNA and 15 μL of LfRNAiMAX were diluted in Opti-
MEM I (Invitrogen, CA, USA) to a total volume of 500 μL,
respectively. The diluted shRNA and LfRNAiMAX were mixed
and incubated at room temperature for 20 min to form
shRNA/LfRNAiMAX complex.
In Vitro Gene Knockdown by Chemically Synthesized
shRNA Transfection. In vitro gene knockdown by chemically
synthesized shRNA was examined with Western blotting as
previously described.22 Briefly, cells (5 × 105 cells/10 cm dish)
were seeded 24 h before shRNA transfection. The cells were
transfected with 5 or 10 nM of either TS shRNA or NS shRNA
in the shRNA/LfRNAiMAX complex. Medium treated cells
were served as control for the experiment. At 72 h post-
transfection, the cells were harvested, washed with chilled PBS,
and resuspended in ice-cold NP-40 lysis buffer (1% NP-40, 50
mM Tris HCl, 150 mM NaCl, 0.25% sodium deoxycholate)
containing protease inhibitor (Sigma-Aldrich, St Louis, Mo,
USA). The protein extract (20 μg per lane) was resolved on
12% SDS-PAGE gel (ATTO Corp., Tokyo, Japan) and
transferred from gel to Hybond-ECL nitrocellulose membrane
(GE Healthcare, CA, USA) and then blocked with Tris-
buffered saline (pH 7.4) containing 5% BSA and 0.05% Tween
20 for 1 h at 25 °C. Membranes were then incubated overnight
at 4 °C with primary antibody [(1:500 for mouse monoclonal
anti-TS antibody (AnaSpec, CA, USA) or 1:5000 for mouse
monoclonal anti-β-actin antibody (Abcam, Tokyo, Japan)].
Then membranes were further incubated with horseradish
peroxidase-conjugated goat antimouse secondary antibody
(1:2000, ICN Biomedical, CA, USA) at 25 °C for 1 h. Finally,
membranes were visualized using the enhanced chemilumi-
nescence system (GE Healthcare, Little Chalfont, UK), and the
obtained images were then analyzed using Multi Gauge v.3.2
(FujiFilm, Tokyo, Japan).
Cell Viability Assay. MSTO-211H cells (2 × 103) were
seeded in 96-well plates in 200 μL of RPMI-1640 medium. At
24 h post-incubation, the cells were transfected with 5 or 10
nM of either TS shRNA or NS shRNA in the shRNA/
LfRNAiMAX complex and further incubated for 24 h. Then, a
fresh medium containing either 0.01 or 10 μg/mL PMX was
added. After different incubation time intervals (24, 48, 72, and
96 h), MTT assay was conducted as described previously.23
Apoptosis Analysis. Cell apoptosis assay was done using
Annexin-V-FITC Apoptosis Detection Kit (Roche) according
to the manufacturer’s recommended protocol. Briefly, cells
(40 000 cells/well) were seeded in six-well plates 24 h before
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chemically synthesized shRNA transfection. The cells were
transfected with 5 or 10 nM of either TS shRNA or NS shRNA
in the shRNA/LfRNAiMAX complex for 24 h. After the
transfection, fresh medium with or without PMX (0.01 μg/mL)
was added, and the cells were further incubated for different
time intervals (24, 48, 72, and 96 h) at 37 °C. Then, the cells
were harvested, washed, and centrifuged for 5 min at 4 °C. The
cell pellets were resuspended in 100 μL of Annexin-V-FLUOS
labeling solution and incubated in dark for 10−15 min at room
temperature. Apoptotic cells were analyzed using flow
cytometer, Guava EasyCyte Mini System (Guava Technologies,
CA, USA), and the sample data were analyzed using CytoSoft
software (Guava Technologies). All experiments were
performed in triplicates.
Preparation of PEG-Coated shRNA-Lipoplexes. Cati-
onic liposome composed of DOPE/CHOL/POPC/DC-6-14
(3:3:2:2, molar ratio) was prepared as described previously.24
The mean diameter and zeta potential for cationic liposomes
were 113.2 ± 10.2 nm and 25.3 ± 0.9 mV (n = 3), respectively,
as determined with Zetasizer Nano ZS (Malvern Instruments
Ltd., UK). For the determination of liposomal phospholipids
concentration, a colorimetric assay was applied.25
For the preparation of shRNA-lipoplexes, shRNA and
cationic liposome were mixed at a molar ratio of 2000:1
(lipid/shRNA) under heavy vortex mixing conditions. The zeta
potential and mean diameter of shRNA-lipoplex were 18.6 ±
1.3 mV and 392.1 ± 37.0 nm (n = 3), respectively. For systemic
application, shRNA-lipoplex was surface-decorated by poly-
ethylene glycol (PEG)-conjugated lipid using a post-insertion
technique as described previously.26 The mean diameter and
zeta potential of PEG-coated shRNA-lipoplex were 403.4 ±
26.2 nm and 16.1 ± 1.8 mV (n = 3), respectively. To identify
the presence of free-shRNA in the prepared PEG-coated
shRNA-lipoplex, electrophoresis was conducted on 2% agarose
gel in 40 mM Tris−acetate buffer containing 1 mM EDTA and
shRNA detection was performed using a UV transilluminator.
The absence of bands related to free shRNA verified that
practically 100% of the shRNA was complexed with PEG-
coated lipoplex under our preparation condition (Figure S1).
The in vitro stability of prepared shRNA-lipoplex was also
investigated in the presence of mouse serum to verify the
stability of our formulated lipoplex (Figure S2).
In Vivo Antitumor Activity by the Combined Treat-
ment with Chemically Synthesized TS shRNA and PMX.
To establish the subcutaneous xenograft model, human MSTO-
211H cells (5 × 106/100 μL PBS) were subcutaneously
inoculated into the back region of 5-week-old male BALB/c
nu/nu mice. The animals were then randomly grouped and
treated with 9% sucrose (control), PEG-coated NS shRNA-
lipoplex, PEG-coated TS shRNA-lipoplex, or PMX as single
agents, or a combination of PMX with either PEG-coated NS
shRNA-lipoplex or PEG-coated TS shRNA-lipoplex. The tumor
size was measured every three days by a caliper, and tumor
volume was estimated using the formula: tumor volume (mm3)
= (length) × (width)2 × 0.5.27 Treated versus control




T C/ (%) [(relative tumor volumes in the treated group
/the control group) 100]
where the relative tumor volume = final tumor volume/initial
tumor volume.28 PEG-coated lipoplex containing TS shRNA or
NS shRNA (40 μg/mouse) was intravenously injected every
other day (on day 7, 9, 11, 13, 15, and 17), and PMX (25 or
100 mg/kg) was intraperitoneally (i.p.) administered days 7−
11 and 14−18, after the tumor cell inoculation. The PMX doses
were selected based on the doses reported in many preclinical
studies12,29 and on our preliminarily experiments (data not
shown). At the end of therapeutic experiments (i.e., when
tumor size exceeded 1500 mm3 in volume), mice were
euthanized, tumors were dissected, and tumor specimens
were analyzed for both the in vivo gene knockdown efficiency
(suppression of TS protein expression) and the induction of
apoptosis within tumor tissue. For the in vivo gene knock down
efficiency of different treatments, Western blotting was
performed as aforementioned. For detection of apoptotic cells
in the tumor tissue, TUNEL assay using In Situ Cell Death
Detection Kit, Texas red (Roche, Indianapolis, IN, USA), was
carried out as described previously.19 Induction of apoptosis in
tumor sections was observed by using a fluorescence micro-
scope (Axiovert 200M; Zeiss, Oberkochen, Germany), and the
numbers of apoptotic cells in each tumor section were
estimated in ten different microscopic fields using analyze
software (AxioVision; Zeiss).
Biodistribution and Tumor Accumulation of PEG-
Coated shRNA-Lipoplexes. To assess the tissue distribution
of PEG-coated TS shRNA-lipoplex, MSTO 211H tumor-
bearing mice were intravenously injected with 3H-CHE-labeled
TS shRNA-lipoplexes (25 mg phospholipid/kg body weight).
Twenty-four hours post-test-lipoplex injection, blood samples
(100 μL) were collected from the retro-orbital sinus, and the
livers, spleens, and tumors were dissected. Radioactivity in
blood and collected tissues was then assayed, as described
previously.30
Statistical Analysis. The data were expressed as mean ±
SD and analyzed using GraphPad InStat View software
(GraphPad Software, CA, USA). A two-tailed unpaired
Student’s t test was performed to determine the significance
of the differences between groups. The level of significance was
set at p < 0.05.
■ RESULTS
Effect of shRNA Transfection on TS Expression in
Human Mesothelioma Cell Line (MSTO-211H). The gene
knockdown efficiency of chemically synthesized TS shRNA on
TS expression was estimated in MSTO-211H cells by using
Western blotting. As shown in Figure 1A, TS shRNA strongly
suppressed TS expression at both shRNA concentrations used
(5 nM and 10 nM), whereas the nonspecific shRNA (NS
shRNA) had no effect on the TS expression at the same
condition. Under this experimental condition, the knockdown
efficacy of TS shRNA was approximately 75%, compared with
the NS shRNA (Figure 1B).
Effect of TS Knockdown on Chemosensitivity of
Mesothelioma MSTO-211H Cell Line to PMX in Vitro.
At first, the cytotoxicity of PMX against MSTO-211H cells was
investigated. As shown in Figure 2, PMX significantly reduced
cell survival in a dose- and time-dependent manner with a
maximum cellular growth inhibition observed at 96 h
postincubation; IC50 at 96 h was 24.64 ± 0.001 ng/mL versus
828.6 ± 0.012 or 38.82 ± 0.001 ng/mL at 48 or 72 h post-
incubation, respectively.
Next, we studied the contribution of TS shRNA-mediated
TS-protein suppression to the cytotoxicity of PMX. MSTO-
211H cells were transfected with chemically synthesized TS
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shRNA, and then treated with PMX (0.01 or 1 μg/mL) for
different times (24, 48, 72, and 96 h). As shown in Figure 3A,B,
at low PMX concentration (0.01 μg/mL; lower than IC50 of
PMX at 96 h), treatment with TS shRNA resulted in an
increased sensitivity of MSTO-211H cells to PMX in a time-
dependent manner, as compared with treatment with NS
shRNA. A maximal cellular growth inhibition (more than 80%)
was reached at 72 h post-transfection (Figure 3A,B). However,
at higher PMX concentration (1 μg/mL) the effect of
suppression of TS expression on the cytotoxicity of PMX was
negligible, where a combination of TS shRNA and PMX did
not show any superior cytotoxicity over PMX alone after any
incubation time (Figure 3C,D). Taken together, the results
suggest that down-regulation of TS protein expression
significantly enhanced the chemosensitivity of mesothelioma
MSTO-211H cells to PMX, raising the chance for reducing
each dose and thereby the total dose of PMX when the
combined therapy is carried out.
Induction of Apoptosis by a Combined Treatment
with Chemically Synthesized TS shRNA and PMX in
Vitro. To gain further insight into the effect of suppression of
TS expression on the chemosensitivity of MSTO-211H cells to
PMX, cellular apoptosis was determined using flow cytometric
analysis of annexin V stained cells at different incubation time
with PMX (24, 48, 72, and 96 h). As shown in Figure 4A,B,
monotreatment with either shRNAs (TS shRNA or NS
shRNA) or PMX did not induce significant apoptosis of
MSTO-211H cells. In the NS shRNA-transfected cells, no
significant change in the percent of apoptotic cells was induced
by PMX treatment. However, in the TS shRNA-transfected
cells, PMX treatment induced a 4.5 -fold increase in the
percentage of apoptotic cells, compared with the cells treated
with combination of NS shRNA and PMX, peaking at 72 h
post-incubation.
In Vivo Antitumor Effect of the Combined Treatment
with Chemically Synthesized TS shRNA and PMX in
MSTO-211H Xenograft Model. To scrutinize the effect of
suppression of TS expression on tumor growth in vivo, the
antitumor efficacy of the combined treatment of TS shRNA
and PMX was evaluated in xenograft mouse model with
MSTO-211H. Monotreatment with NS shRNA did not
suppress tumor growth [T/C (%) = 98.64%] (Figure 5).
Monotreatment with either TS shRNA or PMX or a
combination treatment with NS shRNA and PMX slightly
suppressed tumor growth [T/C (%) = 77.53%, 76.50%, and
81.28%, respectively]. Combination treatment of TS shRNA
and PMX caused a potent tumor growth inhibition [T/C (%) =
37.14%], compared with other treatments (p < 0.01). Notably,
all treatments were well tolerated as manifested by the absence
of remarkable body weight loss among any of the treated
animals (data not shown). These results suggest that combined
treatment with TS shRNA and PMX exerts a potent antitumor
efficacy without causing remarkable toxicity, relating to body
weight loss, in a human mesothelioma xenograft mouse model.
Biodistribution and Tumor Accumulation of Test TS
shRNA-Lipoplex. The biodistribution pattern of PEG-coated
TS shRNA-lipoplex was evaluated following the intravenous
injection of radio-labeled lipoplexes into MSTO-211 tumor-
bearing mice. Test lipoplex distributed/accumulated substan-
tially in the liver and spleen at 24 h post-test-lipoplex injection
(Figure 6). Such preferential accumulation of test lipoplex in
the major eliminating organs might explain the relatively low
blood concentration of test dose. Nonetheless, no remarkable
accumulation of test lipoplex was detected in either kidneys or
lungs (Figure 6). The tumor accumulation of test lipoplex was
also assessed at 24 h post-test-lipoplex injection. As depicted in
Figure 6, test PEG-coated lipoplex accumulated to a certain
extent in the tumor tissue. These results imply that the efficient
antitumor efficacy of a combined treatment of PMX and PEG-
coated TS shRNA is attributed, at least in part, to the efficient
accumulation and/or delivery of TS shRNA within tumor
tissue.
In Vivo Suppression of TS Expression and Induction
of Apoptosis in Tumor Tissue Following Combined
Treatment with TS shRNA and PMX. TS expression levels
in the treated tumors were determined by Western blotting
(Figure 7A). Consistent with the in vitro TS suppression results,
monotreatment with TS shRNA was efficient in suppressing TS
expression in the tumor tissue, while monotreatment with NS
shRNA showed no effect on the expression level of TS. In
addition, a combined treatment with PMX and TS shRNA
Figure 1. Suppression of TS protein expression by the transfection
with chemically synthesized TS shRNA in human mesothelioma
MSTO-211H cell line. (A) TS protein expression in control,
nonspecific (NS) shRNA-, or TS shRNA-transfected MSTO-211H
cells 72 h after transfection, as determined by Western blotting. β-actin
was used for equal loading assessments. (B) Quantitative evaluation of
the percent change in expression levels of TS protein against β-actin
one. Data represents mean ± SD from three independent experiments.
Figure 2. In vitro cytotoxicity of PMX on human mesothelioma
MSTO-211H cells. MSTO-211H cells were incubated with media
containing serial dilutions of PMX for different time intervals (24, 48,
72, or 96 h). After the specified incubation time, the medium was
removed and cell survival was determined by the MTT assay. Data
represent mean ± SD (n = 3).
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significantly suppressed TS expression, compared to a
combined treatment with PMX and NS shRNA (Figure 7A).
To elucidate partly the mechanism of the enhanced
antitumor activity of combined treatment of PMX with
systemic injection of PEG-coated TS shRNA-lipoplex (Figure
5), TUNEL assay was conducted (Figure 7B,C). The combined
treatment of PMX with TS shRNA induced a potent apoptotic
response within the tumor tissue (apoptotic index, 45.7 ±
5.3%), compared to the monotreatment with either PMX or TS
shRNA (apoptotic indexes, 22.1 ± 2.9% and 17.4 ± 3.2%,
respectively) or the combined treatment of NS shRNA with
PMX (apoptotic index, 23.4 ± 4.1%). These results verify the
contribution of apoptosis induction within the tumor tissue to
the potent antitumor efficacy of the combined treatment
against MPM.
■ DISCUSSION
Malignant pleural mesothelioma (MPM) represents an
immense challenge because of its poor prognosis and
remarkable resistance to current therapies.31,32 Clinically,
pemetrexed (PMX) represents a mainstay in most applied
MPM therapeutic strategies. However, its antitumor efficacy is
severely restrained by the development of drug resistance.
Thymidylate synthase (TS), a folate-dependent enzyme, is
considered the main target of PMX.33,34 Many reports have
indicated that TS expression in various tumors is prognostic for
poor outcome in patients treated with PMX.35,36 Recently, we
emphasized that down-regulation of TS expression, using a
chemically synthesized short hairpin RNA (shRNA), signifi-
cantly increased the chemosensitivity of mesotheliomal MSTO-
211H cells to PMX. In addition, we confirmed that the
combined treatment of PMX and locally administered non-
PEGylated TS shRNA-lipoplex substantially alleviated the
progression of orthotopic thoracic tumors compared to each
single treatment.14
Nevertheless, many reports have recently revealed the ability
of MPM cells to metastasize not only to neighboring tissues/
organs such as regional lymph nodes, pericardium, peritoneum,
and chest wall but much farther to reach the brain.15,16 In
addition, the broad invasion of the whole pleura with thoracic
tumors, in tandem with the mechanical stress imparted by
pleural fluids associated with MPM could collectively
compromise the efficacy of locally administered therapeutic
agents. Instead, systemic administration of the therapeutic
agent becomes a prerequisite. In the current study, therefore,
we assessed the effectiveness of “systemically” administered
PEG-coated TS shRNA-lipoplex in sensitizing the mesothelio-
mal cells to the cytotoxic effect of PMX using a subcutaneous
xenograft mouse model. Combined therapy of PMX and
“systemically” administered PEG-coated TS shRNA-lipoplex
showed a superior antitumor efficacy compared with
monotherapy with either agent alone or a combined therapy
with PMX and NS shRNA in MSTO-211H tumor xenograft
mouse model (Figure 5). This potent antitumor efficacy was
achieved mainly via the induction of a potent apoptotic
Figure 3. Effect of TS gene knockdown on the chemosensitivity of human mesothelioma MSTO-211H cells to PMX. MSTO-211H cells were
transfected or not with either 5 or 10 nM of nonspecific (NS) shRNA or TS shRNA. At 24 h post-transfection, fresh media containing PMX (0.01 or
1 μg/mL) were added, and the cells were further incubated for different time intervals (24, 48, 72, or 96 h). Cell viability was then determined by
MTT assay. Data were represented from three independent experiments. ***p < 0.001 versus TS shRNA- or PMX-treated cells.
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response in MSTO-211H tumors (Figure 7B,C). Taken
together, these findings may provide a proof-of-concept that
the combined therapy of PMX and the tumor targeted anti-TS
RNAi system (PEG-coated TS shRNA-lipoplex) represents a
promising alternative therapy to the currently applied dismally
effective therapeutic strategies for the treatment of human
MPM.
Interestingly, we observed that a combined treatment of TS
shRNA and high dose PMX (100 mg/kg) neither additively nor
synergistically cause the tumor growth suppression (Figure S3).
Several studies have revealed that after the exposure to
fluoropyrimidines or antifolate TS inhibitors, the TS protein
expression is induced in preclinical models, both cell lines and
animal models.11,37,38 Thus, small-molecule TS inhibitors can
actually antagonize their therapy by promoting overexpression
of TS. Based on these reports, we assume that treatment with a
high dose of PMX (100 mg/kg) might result in an acute
elevation in TS protein expression level. Thus, TS shRNA
might not be efficient to completely suppress TS protein
expression. However, treatment with a comparatively lower
dose of PMX (25 mg/kg) might not trigger MSTO-211H cells
to elevate TS protein expression level, leading to a superior
tumor growth inhibition (Figure 5). These results obviously
reveal that the therapeutic efficacy of PMX, in combination
with TS shRNA, is mediated in a PMX dose-dependent
manner. However, further studies are urged to precisely
determine the optimal therapeutic window of PMX required
to obtain the maximal antitumor efficacy.
For advanced clinical application of the RNAi technique,
specific and effective delivery of chemically synthesized siRNA
or shRNA to target tumor tissue should be granted. Recently, it
was revealed that nanocarrier systems, such as nanomicelles and
liposomes, containing siRNAs efficiently suppressed tumor
growth in animal models.39−41 In this study, we also confirmed
that PEGylated cationic liposome was efficient in the systemic
delivery of chemically synthesized shRNA to the target site as
reflected by the superior antitumor efficacy (Figure 5) and the
higher apoptotic potential (Figure 7A,B) induced by the
combined therapy of TS shRNA-lipoplex and PMX without
exerting severe side effects. To the best of our knowledge, this
Figure 4. Induction of apoptosis in human mesothelioma MSTO-
211H cells by a combined treatment with PMX and TS shRNA in
vitro. MSTO-211H cells were transfected or not with either 5 or 10
nM of nonspecific (NS) shRNA or TS shRNA. At 24 h post-
transfection, the cells were further treated with 0.01 μg/mL PMX.
Apoptosis was determined by flow cytometry. Data represent mean ±
SD (%) from three independent experiments. *p < 0.05.
Figure 5. Tumor growth suppression by combination therapy of PMX
plus PEG-coated TS shRNA-lipoplexes in human mesothelioma
(MSTO-211H) tumor-bearing mice. Tumor xenograft animal model
was established by subcutaneous inoculation of MSTO-211H cells in
nude mice. PMX (25 mg/kg) was intraperitoneally administered daily
for 5 consecutive days/week for 2 weeks. PEG-coated shRNA-lipoplex
containing either nonspecific (NS) shRNA or TS shRNA (40 μg
shRNA/mouse) was intravenously injected every 2 days (on day 7, 9,
11, 13, 15, and 17 after tumor cell inoculation). For the control group,
sucrose was administered instead of PMX or PEG-coated shRNA-
lipoplexes. Data represent mean ± SD (n = 6). ***p < 0.001.
Figure 6. Biodistribution and intratumoral accumulation of test TS
shRNA-lipoplex. MSTO211H-bearing mice were intravenously
injected with radiolabeled TS shRNA-lipoplex (25 mg phospholipid/
kg body weight). At 24 h after injection, blood and major organs were
collected, and their level of radioactivity was determined. Data
represent mean ± SD (n = 3).
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is the first observation showing the efficacy of PEGylated
cationic liposomes in delivering chemically synthesized shRNA
to tumor tissues following their intravenous administration.
Currently, many therapeutic strategies are available for the
treatment of localized primary tumors including surgical
intervention, radio-/chemotherapy, or a combined approach.
However, effective treatment of primary tumors along with
local or distant metastasis, particularly micrometastases, is
generally limited. Metastases, resulted from local and/or distant
dissemination of malignant cells to the neighboring and/or far
tissues, usually cause tumor recurrence and eventual treatment
failure. An effective strategy to conquer both primary tumor
and metastatic lesions are urgently needed for the complete
cure of cancer. Systemic treatment strategy is one of the
effective therapeutic approaches to treat both primary tumor
and metastatic lesions. In the current study, we evidently
demonstrated that systemically administered TS shRNA was
efficient in the down-regulation of in vivo TS expression. In
addition, the suppression of TS expression is associated with
the increased in vivo antitumor efficacy of PMX in human MPM
tumor-bearing mice model. These results imply that our tumor
targeted anti-TS RNAi system could augment the therapeutic
potential of PMX in many clinical settings. Consequently, the
combined therapy of PMX and anti-TS RNAi system would
represent a promising alternative therapeutic strategy to the
currently applied therapeutic modalities for the treatment of
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■ ABBREVIATIONS
CHOL, cholesterol; DC-6-14, O,O′-ditetradecanoyl-N-(alpha-
trimethyl ammonio acetyl) diethanolamine chloride; DOPE,
dioleoylphosphatidylethanolamine; FBS, fetal bovine serum;
FITC, flourescein isothiocyanate; HRP, horseradish peroxidase;
mPEG2000-DSPE, 1,2-distearoyl-sn-glycero-3-phospho-ethanol-
amine-n-[methoxy (poly ethylene glycol)-2000]; MPM, malig-
nant pleural mesothelioma; MTT, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide; PBS, phosphate buffer saline;
PEG, polyethylene glycol; PMX, pemetrexed; POPC, 1-
Figure 7. Suppression of TS protein and apoptosis induction in the
human mesothelioma cell (MSTO-211H) tumor tissue by a combined
treatment with PMX and PEG-coated TS shRNA-lipoplex. MSTO-
211H tumor-bearing mice were treated in the same way as described
above. When tumor xenograft exceeded 1500 mm3 in volume, mice
were euthanized and tumors were excised. Specimens of tumors were
weighed and analyzed with Western blotting and TUNEL assay. (A)
TS protein expression was determined by Western blot analysis. (B)
Representative immunofluorescent tumor sections (TUNEL, red;
Hoechst 33342, blue). The bar indicates 50 μm. Original
magnification, ×400. (C) Percent of TUNEL-positive cells in the
section. Data represent the mean ± SD. ***p < 0.001 versus sucrose.
###p < 0.01 versus PMX or PEG-coated TS shRNA-lipoplex.
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palmitoyl-2-oleoylphosphatidylcholine; TS, thymidylate syn-
thase
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